Sep. 26, 2011 at 9:12am
ABCNewsACTOSActospioglitazoneFDAbladder cancerBACNbladder cancerRecallRecallsRecallAttorneysGabrielFZambrano@recallattorneys@gfzambranoDiabetes

#ACTOS has been linked to #bladder cancer. The #FDA is evaluating data and alleged link to long term use. In this story ABCNews reports on the potential for 1 in 3 Americans suffering from diabetes and why the numbers continue to rise. ACTOS is used to treat Type 2 Diabetes. A growing body of scientific evidence has linked ACTOS use to bladder cancer and heart problems. ACTOS has been banned in France & Germany by their health authorities. New Zealand is reportedly scheduling a bann as well.

However, the FDA continues to evaluate data on the safety and effectiveness of ACTOS. 

Gabriel F. Zambrano, P.A., is the author and sponsor of this blog and commentary. Gabriel F. Zambrano, P.A., is actively investigating cases of bladder cancer in users of #ACTOS for Type 2 diabetes. Previously posted information on ACTOS appears here.

(Source: abcnews.go.com)

Sep. 25, 2011 at 1:57pm
ACTOSPIOGLITAZONEBACNBladder CancerRecallFDATumblrCancerDiabetes
ACTOS - PIOGLITAZONE - Linked to Bladder Cancer. Recalled in France & Germany.

What more evidence will the FDA need in the US to take stronger action with regard to #ACTOS or #PIOGLITAZONE? Here is my prior post with links to background information.

8:05am
ACTOSActosBACNBACNBladder Cancer Advocacy NetworkRecallRecallsPIOGLITAZONEPioglitazone

#BCAN (Bladder Cancer Advocacy Network) is a support group dedicated to promoting awareness, education and support to the bladder cancer community. #BACN has prepared the informational video above. BACN estimates there are 520,000 bladder cancer survivors in the US. 

The BCAN has noted the following with regard to the FDA: “The Food and Drug Administration (FDA) has found that long-term use of the diabetes drug Actos may increase the risk of bladder cancer. They recommend that Actos should not be used in patients who currently have bladder cancer, and doctors should be cautious when prescribing Actos for patients who have had bladder cancer.”  Notably, BCAN “will continued to monitor the Actos situation, and hopes pharmaceutical companies will be aware of bladder cancer as a potential side effect in future drug safety tests.”

Gabriel F. Zambrano, P.A., has previously posted on the FDA acknowledging that the long term use of #ACTOS may increase the risk of bladder cancer. As someone who lost a parent to cancer, I remain acutely aware of the suffering and uncertainty that comes with a diagnosis. Unfortunately, for many it is a death sentence. With regard to #ACTOS, you can visit prior posts here under ACTOS or via this link.

Sep. 20, 2011 at 9:30am
Actoplus MetActoplus Met XRActosBladder CancerDuetactFDAGlimepirideMetforminPioglitazoneRecallRecallsgabrielfzambranogfzambranorecallattorneysBCANBCANBladder Cancer Advocacy Network
In a continuing evaluation, the FDA issued a warning on the use of #ACTOS (#PIOGLITAZONE) and potential for increased risk of bladder cancer. The drug is manufactured by #TAKEDA. Interestingly, the use of #ACTOS has been limited in France & Germany following studies indicating it posed an increased risk. Apparently, the FDA needs more convincing.  The FDA is continuing an evaluation of data from an ongoing 10 year epidemiological study, as well as a comprehensive review of French studies. #ACTOS is used to treat Type 2 Diabetes in combination with diet and exercise. It is also sold in combination with #metformin as #ACTOPLUS MET, #ACTOPLUS MET XR and #DUETACT (#GLIMEPIRIDE).  Symptoms of bladder cancer include the following: blood or red colored urine; urgency or an urgent need to urinate; pain while urinating; and pain in the lower back or lower abdomen Again, there is no #recall in the US. However, Gabriel F. Zambrano, P.A., the author and sponsor of this blog and commentary will report on any recall. Gabriel F. Zambrano, P.A. is monitoring FDA action and other news on ACTOS with a recall in mind.  Gabriel F. Zambrano, P.A., is investigating cases involving the use of ACTOS (PIOGLITAZONE) and bladder cancer. If you suffer from any of the symptoms above, you should report them to your physician and seek a diagnosis and treatment.  For information and support relating to bladder cancer, contact or review information available from the #BCAN (Bladder Cancer Advocacy Network). The BCAN is dedicated to the support of the bladder cancer community, raising awareness, promoting cancer research and providing educational information. The estimate that bladder cancers it the 5th most diagnosed form of cancer in the US. With regard to #ACTOS, the BCAN notes as follows: “BCAN will continue to monitor the #ACTOS situation, and hopes pharmaceutical companies will be aware of bladder cancer as a potential side effect in future drug safety tests”. Report any symptoms to your physician and seek treatment. BCAN estimates that nearly 70,000 new cases of bladder cancer will be diagnosed in 2011. Further, they estimate nearly 15,000 will die. Again, report symptoms to your physicians and seek diagnosis and treatment.

In a continuing evaluation, the FDA issued a warning on the use of #ACTOS (#PIOGLITAZONE) and potential for increased risk of bladder cancer. The drug is manufactured by #TAKEDA. Interestingly, the use of #ACTOS has been limited in France & Germany following studies indicating it posed an increased risk. Apparently, the FDA needs more convincing.  The FDA is continuing an evaluation of data from an ongoing 10 year epidemiological study, as well as a comprehensive review of French studies.

#ACTOS is used to treat Type 2 Diabetes in combination with diet and exercise. It is also sold in combination with #metformin as #ACTOPLUS MET, #ACTOPLUS MET XR and #DUETACT (#GLIMEPIRIDE). 

Symptoms of bladder cancer include the following:

  • blood or red colored urine;
  • urgency or an urgent need to urinate;
  • pain while urinating; and
  • pain in the lower back or lower abdomen

Again, there is no #recall in the US. However, Gabriel F. Zambrano, P.A., the author and sponsor of this blog and commentary will report on any recall. Gabriel F. Zambrano, P.A. is monitoring FDA action and other news on ACTOS with a recall in mind.  Gabriel F. Zambrano, P.A., is investigating cases involving the use of ACTOS (PIOGLITAZONE) and bladder cancer. If you suffer from any of the symptoms above, you should report them to your physician and seek a diagnosis and treatment. 

For information and support relating to bladder cancer, contact or review information available from the #BCAN (Bladder Cancer Advocacy Network). The BCAN is dedicated to the support of the bladder cancer community, raising awareness, promoting cancer research and providing educational information. The estimate that bladder cancers it the 5th most diagnosed form of cancer in the US. With regard to #ACTOS, the BCAN notes as follows: “BCAN will continue to monitor the #ACTOS situation, and hopes pharmaceutical companies will be aware of bladder cancer as a potential side effect in future drug safety tests”. Report any symptoms to your physician and seek treatment. BCAN estimates that nearly 70,000 new cases of bladder cancer will be diagnosed in 2011. Further, they estimate nearly 15,000 will die. Again, report symptoms to your physicians and seek diagnosis and treatment.